Fatostatin

Research use only, not for human use.

Fatostatin ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2.

Fatostatin ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2.(In Vitro):Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells.(In Vivo):Fatostatin hydrobromide (125B11 hydrobromide) (30 mg/kg; 150 mL; i.p.; daily for 28 days) reduces adiposity, ameliorates fatty liver by reducing triglyceride (TG) storage, and lowers hyperglycemia in ob/ob mice.

Cell Proliferation Assay Cell Line:DU-145 cells Concentration:0.1, 1 μM Incubation Time:3 days Result:Impaired the IGF1-induced growth at an IC50 of 0.1 μM.

Animal Model:Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)Dosage:30 mg/kg; 150 mL Administration:i.p. injection; daily for 28 days Result:Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.

——

GPCR/G Protein

Cannabinoid Receptor

SREBPs

Others-Field

——

298197-04-3

375.33

C18H18N2S·HBr

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (66.61 mM)

Cc1ccc(cc1)c1csc(c2cc(CCC)ncc2)n1.Br

——

(-20℃)

With Ice Pack

≥ 2 years